Published in Crit Rev Oncol Hematol on August 01, 2005
Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol (2008) 1.22
Vaginal rupture caused by transvaginal ultrasonography in follow-up for ovarian cancer. BMJ Case Rep (2009) 1.03
Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol (2010) 1.01
Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis. J Exp Clin Cancer Res (2011) 0.81
The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. Br J Cancer (2010) 0.78
Current status of maintenance therapy for advanced ovarian cancer. Int J Womens Health (2010) 0.77
Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer. Cancer Lett (2011) 0.76
In vitro synergistic action of geldanamycin- and docetaxel-containing HPMA copolymer-RGDfK conjugates against ovarian cancer. Macromol Biosci (2014) 0.75
Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report. Oncol Lett (2014) 0.75
Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. Int J Gynecol Cancer (2012) 0.75
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol (2007) 1.61
Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril (2002) 1.45
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol (2007) 1.40
The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging (2004) 1.33
Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother (2004) 1.30
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.24
Genomic and non-genomic effects of estrogens on endothelial cells. Steroids (2004) 1.20
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis (2005) 1.17
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol (2006) 1.14
Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One (2008) 1.14
Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol (2010) 1.12
Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol (2005) 1.12
Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol (2011) 1.07
Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. Int J Gynecol Cancer (2009) 1.07
Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep (2010) 1.07
Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol (2010) 1.06
New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas (2005) 1.03
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum (2005) 1.02
Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res (2009) 1.01
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol (2008) 1.01
Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol (2007) 1.01
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas (2008) 1.00
Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist (2005) 1.00
Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol (2006) 1.00
Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecol Endocrinol (2012) 1.00
Dose and outcome: the hurdle of neutropenia (Review). Oncol Rep (2006) 1.00
Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology (2010) 0.98
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res (2003) 0.98
Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol (2009) 0.97
Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol (2009) 0.95
Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. J Hematol Oncol (2009) 0.94
Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol Endocrinol (2008) 0.94
Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecol Endocrinol (2006) 0.93
Surgical margins in head and neck squamous cell carcinoma: what is 'close'? Eur Arch Otorhinolaryngol (2012) 0.92
Treatment options in recurrent cervical cancer (Review). Oncol Lett (2010) 0.92
The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol (2004) 0.92
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int (2012) 0.92
Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. Gynecol Endocrinol (2008) 0.90
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. Oncology (2007) 0.90
Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol (2005) 0.90
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2008) 0.89
The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study. Gynecol Oncol (2009) 0.89
Spontaneous cornual pregnancy after homolateral salpingectomy for an earlier tubal pregnancy: a case report and literature review. J Minim Invasive Gynecol (2009) 0.89
Female infertility related to thyroid autoimmunity: the ovarian follicle hypothesis. Am J Reprod Immunol (2011) 0.88
Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol (2006) 0.88
Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer (2008) 0.87
P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res (2006) 0.87
Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem (2008) 0.87
Oestrogen and progestins differently prevent glutamate toxicity in cortical neurons depending on prior hormonal exposure via the induction of neural nitric oxide synthase. Steroids (2009) 0.86
Rapid estrogen actions in the cardiovascular system. Ann N Y Acad Sci (2006) 0.86
Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Hum Fertil (Camb) (2009) 0.86
Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol (2007) 0.85
Estrogen regulates endometrial cell cytoskeletal remodeling and motility via focal adhesion kinase. Fertil Steril (2010) 0.85
Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res (2010) 0.85
Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. Anticancer Res (2010) 0.85
Timing is everything. Gynecol Endocrinol (2007) 0.84
Chromosomal abnormalities in women with premature ovarian failure. Gynecol Endocrinol (2010) 0.84
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril (2010) 0.84
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol (2006) 0.84
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor. Tumori (2011) 0.84
Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol (2005) 0.83
Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res (2006) 0.83
The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge. Crit Rev Oncol Hematol (2009) 0.83
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. J Clin Oncol (2003) 0.83
Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas (2007) 0.83
Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. Anticancer Res (2011) 0.83
Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol (2009) 0.82
Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels. Neuroendocrinology (2006) 0.82
Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. J Cell Mol Med (2009) 0.82
Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study. Int J Gynecol Cancer (2012) 0.81
Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res (2003) 0.81
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. Int J Cancer (2012) 0.81
Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. Crit Rev Oncol Hematol (2011) 0.81
Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit Rev Oncol Hematol (2010) 0.81
Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res (2004) 0.81
Effect of dehydroepiandrosterone on central and peripheral levels of allopregnanolone and beta-endorphin. Fertil Steril (2005) 0.81
Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol (2010) 0.81